Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study. (17th November 2021)

• Record Type: Journal Article
• Authors: Kromer, C.; Wilsmann-Theis, D.; Gerdes, S.; Krebs, S.; Pinter, A.; Philipp, S.; Mössner, R.
• Is Part Of: Journal of dermatological treatment. Volume 32:Number 8(2021)
• Page Start: 878
• Page End: 882
• Publication Date: 2021-11-17
• Subjects: Brodalumab -- ixekizumab -- secukinumab -- IL-17 switching; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2020.1716932
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Introduction: Biologic switching is common in psoriasis patients with non-response to or adverse events under therapy with a biologic. However, evidence on efficacy of switching between newly approved biologics of similar mode of action is scarce. The objective was to assess the efficacy of treating psoriasis patients with an IL-17-receptor A antagonist after failure of any IL-17A antagonist and to identify predictors of treatment response. Methods: A retrospective multicenter chart review on psoriasis patients who received brodalumab after failure of ixekizumab or secukinumab therapy was conducted in five German University Medical centers. Results: Overall, 23 patients were identified. PASI75 response to brodalumab was reached by 47.8% (11/23) of all patients at week 12 and at week 24. 3 patients experienced mild adverse events which did not lead to drug discontinuation. Conclusions: Brodalumab appears to be an efficacious and safe treatment option in psoriasis patients with prior exposure to IL-17A antagonists.